4.35
+0.65(+17.57%)
Currency In USD
| Previous Close | 3.7 |
| Open | 3.7 |
| Day High | 4.38 |
| Day Low | 3.65 |
| 52-Week High | 6.72 |
| 52-Week Low | 2.45 |
| Volume | 12.31M |
| Average Volume | 3.95M |
| Market Cap | 499.62M |
| PE | -4.68 |
| EPS | -0.93 |
| Moving Average 50 Days | 3.2 |
| Moving Average 200 Days | 3.87 |
| Change | 0.65 |
If you invested $1000 in Absci Corporation (ABSI) since IPO date, it would be worth $201.48 as of February 05, 2025 at a share price of $4.35. Whereas If you bought $1000 worth of Absci Corporation (ABSI) shares 3 years ago, it would be worth $589.43 as of February 05, 2025 at a share price of $4.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference
GlobeNewswire Inc.
Jan 22, 2025 1:00 PM GMT
VANCOUVER, Wash. and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Guggenheim Securities SMID Cap Bi
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
GlobeNewswire Inc.
Jan 10, 2025 12:30 PM GMT
Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class therapeuticsVANCOUVER, Wash. and PARIS, Jan. 10, 2025
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery
GlobeNewswire Inc.
Jan 08, 2025 12:00 PM GMT
$20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm SoftwareVANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (N